Publication: 2247

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Citation:: J Clin Oncol vol 34 (10) 1034-1042

Year:: 2016
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:: 2093 is parent abstract. Research reported in this publication was supported by GlaxoSmithKline (GSK)

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 5

Parents:: 2093 2147
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: U10 CA180802, U10 CA180821, U10CA180882, P30 CA008748, U10 CA180882, U10CA180821, U10 CA180867, U10 CA025224, CA025224

Corr. Author:
Authors:: Martine Piccart-Gebhart Eileen Holmes José Baselga Evandro de Azambuja Amylou C. Dueck Giuseppe Viale Jo Anne Zujewski Aron Goldhirsch Alison Armour Kathleen I. Pritchard Ann E. McCullough Stella Dolci Eleanor McFadden Andrew P. Holmes Liu Tonghua Holger Eidtmann Phuong Dinh Serena Di Cosimo Nadia Harbeck Sergei Tjulandin Im Young-Hyuck Chiun-Sheng Huang Véronique Diéras David W. Hillman Antonio C. Wolff Christian Jackisch Istvan Lang Michael Untch Ian Smith Frances Boyle Binghe Xu Henry Gomez Thomas Suter Richard D. Gelber Edith A. Perez

Networks:: KANSAS, LAPS-MD017, LAPS-MN026, LAPS-NY016, PR028

Study: NCCTG-N063D
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Rc, Bc6, ORIGINAL REPORTS, Rapid Communication